Aurobindo Files First Biosimilar In Europe With Pegfilgrastim

Indian Giant’s CuraTeQ Subsidiary Files BP14 Neulasta Rival With EMA

 
• By Dave Wallace

Aurobindo has submitted its first biosimilar application to the EMA, with the Indian company’s CuraTeQ subsidiary filing its BP14 pegfilgrastim rival to Neulasta.

EU European Union flag waving in wind at mountain
Aurobindo has passed a milestone with its first EU biosimilar filing • Source: Alamy

More from Biosimilars

More from Products